Natural history study of growth in children with type II collagen disorders
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This study follows children with certain inherited “type II collagen” conditions that cause short height, to better understand how growth changes over time. It does not test a new treatment; it mainly tracks health and growth so doctors can learn what to expect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child has a confirmed type II collagen disorder that causes short stature (such as Kniest, SEDc, SEMD, SED, or hypochondrogenesis)
- Child is younger than 13 years old at the time of consent/assent
- Parent/guardian can sign consent, and the child can give assent if required
- Child can attend scheduled study visits and follow study instructions
- No other non–type II-collagen cause of short height
- Not using growth-related medicines in the last 12 months (growth hormone, IGF-1, anabolic steroids, or similar)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at a surgery that slows future height growth in adolescents who are very tall and still growing. It may help reduce how much more height they may gain by limiting growth at the knee/leg growth plates.
This study is for children with hypochondroplasia, a condition that causes short stature. It will look at how the condition changes over time and aims to better understand it, with the goal of finding new treatments.
this study is a long-term extension of the main study for the drug which from Bio? bi? whatever? in the name? by?...????
This study looks at how the body’s growth signals (growth hormone and related proteins) work in children. It may help researchers understand growth differences in kids who are healthy or have certain growth-related conditions.
This trial tests a new medicine for children with achondroplasia (a common form of dwarfism). It aims to see if the drug can improve growth. The study is for children aged 2.5 to under 11 years old who have not started puberty and can walk without help.
This study looks at your child’s growth history and performs genetic testing to better understand why some children are very short. It may help researchers identify possible underlying causes and improve care, using blood samples from the child and both parents.
Hear when a new SEDC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.